echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > ​Copy PD-1?

    ​Copy PD-1?

    • Last Update: 2022-01-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The TIGIT target is becoming the next "sweet pastry" to go overseas
    .


    On the evening of January 10, 2022, Junshi Bio announced that it has expanded the scope of cooperation with Coherus, and Coherus has launched the licensing option of JS006 (TIGIT monoclonal antibody) in the United States and Canada


    The TIGIT target is becoming the next "sweet pastry" to go overseas


    01.


    Wang Lai, head of BeiGene’s research and development , has the most hope in BeiGene’s pipeline is the TIGIT target


    02.


    Roche and Merck are the top players in the combination of PD-(L)1+TIGIT


    03.


    In addition, as the licensor, Innovent also has another TIGIT monoclonal antibody currently in Phase 1 clinical trials


    04.


    Their next choice is to "buy", which is the answer that the E-pharmaceutical manager got from several companies that have TIGIT in research but no PD-1 research
    .
    They are optimistic about the combination potential of TIGIT, and PD-1 is now readily available
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.